
    
      During the 12-week treatment period, subjects will record daily assessments including:
      frequency and timing of bowel movements; sensation and complete bowel emptying; consistency
      of bowel movements; degree of straining, worst abdominal pain, abdominal discomfort,
      abdominal bloating, abdominal fullness and abdominal cramping. Subjects will also record
      weekly assessments including: adequate relief of IBS severity, and constipation severity.

      At the end of the 12-week treatment period, there will be a 4-week randomized withdrawal
      period in which subjects who complete the study in Tenapanor group will be randomized to
      either Tenapanor 50mg BID or placebo BID (1:1) and subjects who complete the study in the
      placebo group will be assigned to receive Tenapanor 50mg BID.
    
  